Johnson & Johnson $JNJ Shares Sold by Brown Miller Wealth Management LLC

Brown Miller Wealth Management LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 36.5% in the 3rd quarter, Holdings Channel reports. The firm owned 4,826 shares of the company’s stock after selling 2,769 shares during the quarter. Brown Miller Wealth Management LLC’s holdings in Johnson & Johnson were worth $895,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson in the third quarter worth $28,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the second quarter worth about $27,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $35,000. Finally, Signature Resources Capital Management LLC lifted its position in Johnson & Johnson by 262.9% in the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a research note on Monday, October 20th. Morgan Stanley increased their price target on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Finally, Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $212.62.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $204.32 on Tuesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $215.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $492.26 billion, a P/E ratio of 19.72, a PEG ratio of 2.13 and a beta of 0.34. The business’s 50-day moving average price is $201.45 and its 200 day moving average price is $183.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.